Abstract |
High-dose thiotepa was given as a single agent at a total dose of 1125 mg/m2 with autologous bone marrow rescue to nine patients with recurrent/refractory/poor risk pediatric malignancies ( primitive neuroepithelial tumor ( PNET), two; neuroblastoma, one; Wilms' tumor, one; osteosarcoma, one; Ewing's sarcoma one, Hodgkin's disease one, high-grade glioma, two). The response rate in these heavily pretreated patients was 71% (five out of seven evaluable patients) including two complete responses (Wilms', glioma), three partial responses ( osteosarcoma, Ewing's sarcoma, Hodgkin's disease), and two with stable disease ( PNET, glioma). The median duration of response was 2.5 months. The extramedullary toxicity was acceptable with symptoms mainly of skin and gastrointestinal tract. The data indicate that high-dose thiotepa is effective in several types of recurrent pediatric solid tumors, and merits further evaluation in combination regimens.
|
Authors | U M Saarinen, L Hovi, A Mäkipernaa, P Riikonen |
Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 8
Issue 5
Pg. 369-76
(Nov 1991)
ISSN: 0268-3369 [Print] England |
PMID | 1768972
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adolescent
- Bone Marrow Transplantation
(adverse effects)
- Child
- Child, Preschool
- Combined Modality Therapy
- Evaluation Studies as Topic
- Female
- Graft Survival
- Humans
- Infections
(etiology)
- Male
- Neoplasms
(drug therapy, surgery)
- Skin
(drug effects)
- Thiotepa
(administration & dosage, adverse effects)
- Transplantation, Autologous
|